🇺🇸 FDA

Intelligence · Clinical Pipeline

Alnylam Netherlands Pipeline

All ClinicalTrials.gov programs at Alnylam Netherlands — phase, modality, and trial IDs.

Programs
84

Quick answer

Alnylam Netherlands has 84 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. VIR-2218

    Alnylam Netherlands B.V.

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  2. VIR-2218

    Alnylam Netherlands B.V.

    Chronic Hepatitis B

    phase 2 small molecule completed

    2 trials

  3. Zilebesiran

    Alnylam Netherlands B.V.

    Mild to Moderate Hypertension

    phase 2 small molecule completed

    1 trial

  4. Zilebesiran

    Alnylam Netherlands B.V.

    High Cardiovascular Risk

    phase 2 small molecule completed

    1 trial

  5. cemdisiran

    Alnylam Netherlands B.V.

    Atypical Hemolytic Uremic Syndrome

    phase 2 small molecule terminated

    2 trials

  6. phosphate-buffered saline for SC administration

    Alnylam Netherlands B.V.

    Hereditary Hemorrhagic Telangiectasia (HHT)

    phase 2 small molecule active

    1 trial

  7. A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOAD

    Alnylam Netherlands B.V.

    Early-onset Alzheimer's disease (EOAD)

    phase 1 other active

    1 trial

  8. A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer’s Disease

    Alnylam Netherlands B.V.

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  9. A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

    Alnylam Netherlands B.V.

    Advanced or Metastatic Hepatocellular Carcinoma

    phase 1 other active

    1 trial

  10. A Study to Evaluate ALN-HTT02 in Adult Patients with Huntington’s Disease

    Alnylam Netherlands B.V.

    Huntington’s disease

    phase 1 other active

    1 trial

  11. ALN-4285

    Alnylam Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  12. ALN-4915

    Alnylam Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  13. ALN-5288

    Alnylam Netherlands B.V.

    Alzheimer's Disease

    phase 1 small molecule active

    1 trial

  14. ALN-AAT

    Alnylam Netherlands B.V.

    Antitrypsin Deficiency Liver Disease

    phase 1 small molecule terminated

    1 trial

  15. ALN-AGT01

    Alnylam Netherlands B.V.

    Hypertension

    phase 1 small molecule completed

    1 trial

  16. ALN-AGT01 RVR

    Alnylam Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  17. ALN-APP

    Alnylam Netherlands B.V.

    Early-Onset Alzheimer Disease

    phase 1 small molecule active

    1 trial

  18. ALN-BCAT

    Alnylam Netherlands B.V.

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  19. ALN-HBV

    Alnylam Netherlands B.V.

    Hepatitis B

    phase 1 small molecule terminated

    1 trial

  20. ALN-HSD

    Alnylam Netherlands B.V.

    Nonalcoholic Steatohepatitis

    phase 1 small molecule terminated

    1 trial

  21. ALN-HTT02

    Alnylam Netherlands B.V.

    Huntington's Disease

    phase 1 small molecule active

    1 trial

  22. ALN-PCS02

    Alnylam Netherlands B.V.

    Elevated LDL-Cholesterol (LDL-C)

    phase 1 small molecule completed

    1 trial

  23. ALN-PCSSC

    Alnylam Netherlands B.V.

    Hypercholesterolemia

    phase 1 small molecule completed

    1 trial

  24. ALN-TTR01

    Alnylam Netherlands B.V.

    Transthyretin Mediated Amyloidosis (ATTR)

    phase 1 small molecule completed

    1 trial

  25. ALN-TTR02

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

  26. ALN-TTRSC (revusiran)

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

  27. ALN-TTRSC02

    Alnylam Netherlands B.V.

    Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)

    phase 1 small molecule completed

    1 trial

  28. ALN-TTRSC04

    Alnylam Netherlands B.V.

    Transthyretin-Mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

  29. ALN-VSP02

    Alnylam Netherlands B.V.

    Solid Tumors

    phase 1 small molecule completed

    2 trials

  30. Computer algorithm for ATTR

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis

    phase 1 other terminated

    1 trial

  31. Givosiran

    Alnylam Netherlands B.V.

    Acute Intermittent Porphyria (AIP)

    phase 1 small molecule completed

    1 trial

  32. Pozelimab

    Alnylam Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

  33. givosiran (ALN-AS1)

    Alnylam Netherlands B.V.

    Acute Intermittent Porphyria

    phase 1 small molecule completed

    1 trial

  34. patisiran

    Alnylam Netherlands B.V.

    Polyneuropathies

    phase 1 small molecule completed

    1 trial

  35. patisiran (ALN-TTR02)

    Alnylam Netherlands B.V.

    Transthyretin (TTR)-Mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

  36. 99mTc-pyrophosphate Scintigraphy

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis

    other active

    1 trial

Frequently asked questions

How many pipeline programs does Alnylam Netherlands have?

84 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.